Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B

Publisher： Karger

E-ISSN： 1423-0100|51|4|293-298

ISSN： 0300-5526

Source： Intervirology, Vol.51, Iss.4, 2008-11, pp. : 293-298

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lamivudine and Famciclovir Combination Therapy with or without Addition of Interferon-alpha-2b for HBeAg-positive Chronic Hepatitis B: A Pilot Study

By Sangfelt Per   Uhnoo Ingrid   Hollander Anna   Lindh Gudrun   Weiland Ola  

Scandinavian Journal of Infectious Diseases, Vol. 34, Iss. 7, 2002-07 ,pp. : 505-511

Informa Healthcare

Access to resources Recommend Favorite

Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg‐positive chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 473-481

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Follow-Up of HBeAg-Positive Young Adult Japanese Patients Treated with Corticosteroid Withdrawal Therapy for Chronic Hepatitis B

By  

Intervirology, Vol. 49, Iss. 6, 2006-10 ,pp. : 339-345

Karger

Access to resources Recommend Favorite

Long-Term Results of Lamivudine Monotherapy in Korean Patients with HBeAg-Positive Chronic Hepatitis B: Response and Relapse Rates, and Factors Related to Durability of HBeAg Seroconversion

By  

Intervirology, Vol. 48, Iss. 6, 2005-07 ,pp. : 341-349

Karger

Access to resources Recommend Favorite

Clinical outcomes after interruption of entecavir therapy in HBeAg‐negative chronic hepatitis B patients with compensated cirrhosis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 10, 2015-11 ,pp. : 1182-1191

John Wiley & Sons Inc

Access to resources Recommend Favorite